Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 22 February 2021

Situation Report No. 237 - Kingdom of Bahrain

23th of February, 2021

World Health Organization

	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Total	111,279,860	2,466,639	6,235,740	142,615
New	338,695	7,593	27,068	375

Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	118,530	110,827	429	7,274	69	3,008,379
New	721	820	6	-	-	14,191

HIGHLIGHTS

- The mortality were: 5 Bahraini citizens [4 male (44, 50, 54 and 59 years old) and 1 female (29 years old)], and a 59 years old male expatriates.
- Increasing number of citizens and residents continue to take COVID-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed that total number of individuals vaccinated as of 22 February 2021 is 278,222.
- The National Institution for Human Rights (NIHR) confirmed that all precautionary measures have been carried out to protect health and safety of inmates in Bahrain during the pandemic.
- Assistant Chief of Public Security called on the public to comply with the precautionary measures against COVID-19.
- Nationwide inspections intensified to identify COVID-19 protocols violators, warning of new Coronavirus strains spreading rapidly among younger people.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO :Emergency Global Supply Chain System (COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmun oassay; see link below.
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises; see link below
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 place bo-controlled vaccine trials and trial unblinding; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health; see link below.
- WHO: Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing; see link below.
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum; see link below.
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers; see link below.
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19; see link below.
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum; see link below.
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines; see link below.
- WHO: Online global consultation on contact tracing for COVID-19, 9-11 June 2020; see link below.
- WHO: COVID-19 Virtual Press conference transcript - 1 February 2021; see link below.
- WHO: Contact tracing in the context of COVID-19; see link below.
- WHO: Background document on the mRNA-1273 vaccine (Moderna) against COVID-19; see link below.
- WHO: COVID-19- Occupational health and safety for health workers; see link below.
- WHO: Weekly operational update on COVID-19 - 13 February 2021; see link below.
- WHO lists two additional COVID-19 vaccines for emergency use and COVAX roll-out; see link below.
- WHO: G7 leaders commit US$ 4.3 billion to finance global equitable access to tests, treatments and vaccines in 2021; see link below.
- WHO Director-General's statement on Tanzania and COVID-19; see link below.



IMPORTANT LINKS

- **Daily COVID-19 updates on MoH website:** https://www.moh.gov.bh/
- **WHO's COVID-19 weekly situation reports:** https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200817-weekly-epi-update 1.pdf?sfvrsn=b6d49a76_4
- **WHO's COVID-19 Dashboard:** https://covid19.who.int/
- **WHO: New research helps to increase understanding of the impact of COVID19 for pregnant women and their babies:** http://www.who.int/news-room/detail/01-09-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies
- **WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic** : https://bit.ly/25vds0r
- **WHO : Emergency Global Supply Chain System(COVID-19) catalogue:** https://www.who.int/publications/i/item/emergency-global-supply-chain-system-(covid-19)-catalogue
- **WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmun oassays** :bit.ly/2IfOjVF
- **WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination** :bit.ly/2J0wxWQ
- **WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises:** https://www.who.int/publications/i/item/9789240017467
- **COVID-19 vaccine introduction and deployment costing tool:** https://www.who.int/publications/i/item/10665337553
- **WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19placebo-controlled vaccine trials and trial unblinding:** https://www.who.int/publications/i/item/WHO-2019-nCoV-Policy_Brief-ELD_placebo-controlled_vaccine_trials-2020.1
- **WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19:** https://www.who.int/publications/i/item/WHO-2019-nCoV-Risk-based_international_travel-Assessment_tool-2020.1
- **WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access:** https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access
- **WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health:** https://www.who.int/publications/i/item/9789240018440
- **WHO: Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing:** https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1
- **WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum:** https://www.who.int/news/item/12-01-2021-global-scientists-double-down-on-sars-cov-2-variants-research-at-who-hosted-forum
- **WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers:** https://www.who.int/publications/i/item/WHO-2019-nCoV-essential_health_services-monitoring-2021.1
- **WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19:** https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19
- **WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum:** https://www.who.int/news/item/16-01-2021-scientists-tackle-vaccine-safety-efficacy-and-access-at-global-r-d-forum
- **WHO: Emergency Committee on COVID-19 advises on variants, vaccines:** https://www.who.int/news/item/15-01-2021-emergency-committee-on-covid-19-advises-on-variants-vaccines
- **WHO: Online global consultation on contact tracing for COVID-19, 9-11 June 2020:** https://www.who.int/publications/i/item/online-global-consultation-on-contact-tracing-for-covid-19-9-11-june-2020
- **WHO: COVID-19 Virtual Press conference transcript - 1 February 2021:** https://www.who.int/publications/m/item/covid-19-virtual-press-conference-transcript---1-february-2021
- **WHO: Contact tracing in the context of COVID-19:** https://www.who.int/publications/i/item/contact-tracing-in-the-context-of-covid-19
- **WHO: Background document on the mRNA-1273 vaccine (Moderna) against COVID-19:** https://www.who.int/publications/i/item/background-document-on-the-mrna-1273-vaccine-(moderna)-against-covid-19
- **WHO: COVID-19- Occupational health and safety for health workers:** https://www.who.int/publications/i/item/WHO-2019-nCoV-HCW_advice-2021.1
- **WHO: Weekly operational update on COVID-19 - 13 February 2021:** https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19---13-february-2021
- **WHO lists two additional COVID-19 vaccines for emergency use and COVAX roll-out:** https://www.who.int/news/item/15-02-2021-who-lists-two-additional-covid-19-vaccines-for-emergency-use-and-covax-roll-out
- **WHO: G7 leaders commit US$ 4.3 billion to finance global equitable access to tests, treatments and vaccines in 2021:** https://www.who.int/news/item/19-02-2021-g7-leaders-commit-us-4.3-billion-to-finance-global-equitable-access-to-tests-treatments-and-vaccines-in-2021
- **WHO Director-General's statement on Tanzania and COVID-19:** https://www.who.int/news/item/20-02-2021-who-director-general-s-statement-on-tanzania-and-covid-19



IMPORTANT CONTACTS

- **The National Focal Person is Dr. Najat Mohamed Abulfateh, email**: NAli5@health.gov.bh
- **International Health Regulations focal person is Dr. Kubra Salman, email:** knasser@health.gov.bh